LncRNA GHET1 predicts a poor prognosis of the patients with non-small cell lung cancer.
CONCLUSIONS: LncRNA GHET1 might be a biomarker and molecular target of NSCLC, providing a potential therapeutic target of NSCLC.
PMID: 29762836 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Non-Small Cell Lung Cancer | Study